{
    "2018-02-26": [
        [
            {
                "time": "",
                "original_text": "中上协“2017年度最受投资者尊重的上市公司评选”入围名单揭晓",
                "features": {
                    "keywords": [
                        "上市公司",
                        "评选",
                        "投资者"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：市场如期反弹 我们组合继续表现突出",
                "features": {
                    "keywords": [
                        "医药生物",
                        "反弹",
                        "组合"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级]医药行业周报：反弹后的策略：把握产业趋势 关注性价比",
                "features": {
                    "keywords": [
                        "医药",
                        "反弹",
                        "策略",
                        "性价比"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[领先大市-A评级]医药行业每周观点：关注业绩超预期及估值增速具备高性价比的投资机会 首推葵花药业和济川药业",
                "features": {
                    "keywords": [
                        "医药",
                        "业绩",
                        "估值",
                        "性价比",
                        "葵花药业",
                        "济川药业"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[强于大市评级]医药生物行业研究周报：震荡中拥抱低估值高成长的“安全标的”",
                "features": {
                    "keywords": [
                        "医药生物",
                        "震荡",
                        "低估值",
                        "高成长",
                        "安全标的"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}